Shamez Ladhani to Antibodies, Viral
This is a "connection" page, showing publications Shamez Ladhani has written about Antibodies, Viral.
Connection Strength
0.181
-
Serological surveillance of SARS-CoV-2: Six-month trends and antibody response in a cohort of public health workers. J Infect. 2021 05; 82(5):162-169.
Score: 0.022
-
Persistence of SARS-CoV-2 N-Antibody Response in Healthcare Workers, London, UK. Emerg Infect Dis. 2021 04; 27(4):1155-1158.
Score: 0.022
-
SARS-CoV-2 infection and transmission in primary schools in England in June-December, 2020 (sKIDs): an active, prospective surveillance study. Lancet Child Adolesc Health. 2021 06; 5(6):417-427.
Score: 0.022
-
Robust antibody responses in 70-80-year-olds 3 weeks after the first or second doses of Pfizer/BioNTech COVID-19 vaccine, United Kingdom, January to February 2021. Euro Surveill. 2021 03; 26(12).
Score: 0.022
-
Antibodies to SARS-CoV-2 protect against re-infection during outbreaks in care homes, September and October 2020. Euro Surveill. 2021 02; 26(5).
Score: 0.022
-
Seroprevalence of SARS-CoV-2 antibodies in children of United Kingdom healthcare workers: a prospective multicentre cohort study protocol. BMJ Open. 2020 11 19; 10(11):e041661.
Score: 0.022
-
Seroprevalence of SARS-CoV-2 antibodies in children: a prospective multicentre cohort study. Arch Dis Child. 2021 07; 106(7):680-686.
Score: 0.022
-
Duration of infectiousness and correlation with RT-PCR cycle threshold values in cases of COVID-19, England, January to May 2020. Euro Surveill. 2020 08; 25(32).
Score: 0.021
-
Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection. Nat Immunol. 2021 05; 22(5):620-626.
Score: 0.006